Sunday, September 24, 2023
News
NEWS HOME
PRN INDIA
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
  SocialTwist Tell-a-Friend  
   

EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days

Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022

LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib. Leniolisib has been studied for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents age 12 or older in the European Economic Area (EEA). Pharming is on track and plans to submit its MAA for leniolisib to the EMA in October 2022.

Pharming Group logo

Accelerated assessment reduces the timeframe for the CHMP to review an MAA from 210 days to 150 days. The EMA will grant, upon request, accelerated assessment of an MAA if they decide the product is of major interest for public health and therapeutic innovation.

The clinical development for leniolisib includes positive data from a Phase II/III study of the product, which met both its co-primary endpoints in the target patient population of evaluated reduction in lymph node size and correction of immunodeficiency. The primary efficacy results demonstrated clinical efficacy of leniolisib over placebo with a statistically significant reduction from baseline in the log10 transformed sum of product of diameters (SPD) in the index lymphadenopathy lesions (p=0.0012) and normalization of immune dysfunction, as evidenced by increased proportion of naïve B cells from baseline (p<0.0001). The shrinking of lymphadenopathy lesions and increased proportion of naïve B cells are important in patients as they indicate a reduction in APDS disease markers.

In the study, leniolisib was generally well-tolerated, with the majority of reported adverse events in both treatment groups classified as mild. There were no adverse events that led to discontinuation of study treatment, there were no deaths, and the incidence of serious adverse events (SAEs) was lower in the leniolisib group than the placebo group. None of the SAEs were suspected to be related to study treatment.

Anurag Relan, Chief Medical Officer of Pharming, commented:

"The acceptance of an accelerated regulatory review for leniolisib underlines the high unmet need for patients with APDS, with the product potentially being the first approved treatment for this rare disease. This is an important milestone for the APDS community and for Pharming and is built on the successful Phase II/III data, which we first reported in February 2022. We remain focused on progressing leniolisib through the regulatory review process, with our MAA on track for submission in October of this year, as we seek to make this important new product available to immunologists, hematologists, and their patients in Europe."

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS)

APDS is a rare primary immunodeficiency that affects approximately one to two people per million. Also known as PASLI, it is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway.1,2 Balanced signaling in the PI3Kδ pathway is essential for physiological immune function. When this pathway is hyperactive, immune cells fail to mature and function properly, leading to immunodeficiency and dysregulation.1,3 APDS is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.

About Leniolisib

Leniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immunomodulating and potentially anti-neoplastic activities. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3). PIP3 serves as an important cellular messenger specifically activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Unlike PI3Kα and PI3Kβ, which are ubiquitously expressed, PI3Kẟ and PI3Kγ are expressed primarily in cells of hematopoietic origin. The central role of PI3Kẟ in regulating numerous cellular functions of the adaptive immune system (B-cells and, to a lesser extent, T cells) as well as the innate immune system (neutrophils, mast cells, and macrophages) strongly indicates that PI3Kẟ is a valid and potentially effective therapeutic target for several immune diseases. To date, leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com.

Forward-looking Statements

This press release contains forward-looking statements, including with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, Pharming's ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

References

1. Lucas CL, et al. Nat Immunol. 2014;15:88-97.
2. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.
3. Nunes-Santos C, et al. J Allergy Clin Immunol. 2019;143(5):1676-1687.
4. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.
5. Maccari ME, et al. Front Immunol. 2018;9:543.
6. Jamee M, et al. Clin Rev Allergy Immunol. 2020;59(3):323-333.
7. Condliffe AM, Chandra A. Front Immunol. 2018;9:338.

Logo - https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpg

More News by PR Newswire India

France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival

CGTN: 'Heart to Heart': How can Hangzhou Asiad boost unity, friendship across Asia?

Education Icon Awards 2023 organized by Kiteskraft Productions LLP

Office of the Executive Committee of the WMC: Anhui Strengthens Scientific and Technological Innovation Capacity to Attract Multinational Enterprises

SAUDI ARABIA UNVEILS TOP TOURISM LEADERS AND GLOBAL MINISTERS IN SPEAKER LINEUP FOR WORLD TOURISM DAY 2023

TECNO Globally Launches PHANTOM V Flip 5G: Representing Flip in Style and Perfect in Pocket

Education Icon Awards 2023 organized by Kiteskraft Productions LLP

Office of the Executive Committee of the WMC: Anhui Strengthens Scientific and Technological Innovation Capacity to Attract Multinational Enterprises

SAUDI ARABIA UNVEILS TOP TOURISM LEADERS AND GLOBAL MINISTERS IN SPEAKER LINEUP FOR WORLD TOURISM DAY 2023

TECNO Globally Launches PHANTOM V Flip 5G: Representing Flip in Style and Perfect in Pocket

TECNO Celebrates Iconic Innovation and Design at its Flip In Style Flagship Product Launch

Harnessing AI to Find Ideal Business Partners in International Trade

Huawei Proposes Key Measures to Boost Digital Productivity and Accelerate Electric Power Intelligence

Xinhua Silk Road: Bailian Group plays crucial role in Shanghai's consumer market development

Asia Pacific View's "Skill-Show" by Foreign Bloggers at Vocational Skills Competition of the People's Republic of China in Tianjin

Grow with Huawei Cloud: Accelerating GTM and Sales with Empowered Benefits

Biomerics Announces Completion of 100,000 sq. ft. Expansion of Brooklyn Park, MN, Facility

Hisense Showcases Hero Mini-LED ULED Television, The U8, at 'Portals to Beyond' Event in South Africa

Ghana launches USD 550 billion Energy Transition and Investment Plan for achieving net-zero emissions, creating 400,000 jobs by 2060

UN WOMEN'S HEFORSHE ALLIANCE CALLS TO RESPECTFULLY DISRUPT THE PATRIARCHICAL STRUCTURES AND STATUS QUO

SHEIN TO PRESENT FALL/WINTER 2023 COLLECTIONS THROUGH LIVESTREAM FASHION SHOW, SHEIN LIVE: FRONT ROW

/DISREGARD RELEASE: Monika Alcobev Limited/

More than 70% of farmers have already seen large impacts of climate change on their farm, new global research across 8 countries reveals

Orion Innovation Names Mark Berler EVP of Growth to Accelerate Strategic Initiatives and Expansion Plans

World Investment Forum to incentivize global investment in sustainable development

Exploring F5G Evolution, Huawei Launches Three Enterprise Optical Network Solutions

ATTENTION AMAYA INC. SHAREHOLDERS FROM 2016 - Settlement Approval Hearing to be held

Huawei Connect TECH4ALL Summit Explores How Technology and Partnerships Enable Inclusion and Sustainability

Xinhua Silk Road: China services trade fair provides huge opportunities for global businesses

New Levi's® Campaign 'For Now, For A Lifetime' Celebrates Moments of Instincts featuring Deepika Padukone

ACG appoints Borja Guerra as vice president of international sales at ACG Engineering

Hisense and Paris Saint-Germain Celebrates the Renewal of Their Partnership

Brio Technologies Wins Google Cloud DEI Partner of the Year in APAC Award

AstaGuru's Upcoming 'Present Future' Contemporary Art Auction Is An Eclectic Medley of Works by Leading Indian Contemporary Artists

Huawei's Xinghe Network Accelerates Industry Intelligence

Huawei Releases White Paper "Striding Towards an Intelligent World" for the Financial Industry

ACX wins Environmental Finance's Best Carbon Exchange award for third consecutive year

iQIYI Unveils 282 New Titles at 2023 iJOY Conference, Prioritizing Relatable Content for Ordinary People

NHN Corporation Steps into Web3 with Sui

Pixalate Q2 2023 Ad Fraud Benchmarks for Web Traffic: North America Reports Highest Desktop Invalid Traffic Rate at 13%, Followed by Asia-Pacific

Leading Industry Experts Set to Convene for Bahrain's Fintech Forward 2023

Innokin Wins "Golden Leaf Award for Innovation" at GTNF 2023 for World's First Metal-free Conductive Ceramic Coil

Glenmark Pharma announces Proposed Divestment of Majority Stake in Glenmark Life Sciences

The First Competition of the Asian Games held in Ningbo, Zhejiang

BRACCO IMAGING S.p.A. ANNOUNCES GLOBAL AGREEMENT WITH SUBTLE MEDICAL, Inc.

Huawei Launches Intelligent Architecture and Intelligent E&P Solution for Oil and Gas Industry

Zefr Expands TikTok Product to Provide Advertisers With Suitability Exclusions, in Collaboration with TikTok's Inventory Filter

Black Box strengthens India presence with new Center of Excellence

Bharti AXA Life Insurance launches Wealth Maximizer -- a return of all charges ULIP plan -- exclusively available on PolicyBazaar

Lacework Announces That It Has Been Selected by TSB Bank to Secure Its Cloud Infrastructure

#PlumeStrong Cycling Challenge 2023 Raises €550,000 to Benefit Children Affected by the Turkey-Syria Earthquake

Caretta Research: 'Super Aggregation' will be Key to MVPDs' Success in Next Decade

Huawei's David Wang: Accelerate Intelligence with Custom-built AI Models for All Industries

Bushmills Glassware Named the Official Celebration Partner of IndianOil Grand Prix of India

Adidas and Geek+ Inaugurate a New State-of-the-Art Automated Distribution Center

Huawei Releases the White Paper on Architecture for Intelligent Transformation of Public Services

HUAWEI eKit Joins Hands with Distribution Partners to Explore Unlimited Opportunities in the SME Market

Xinhua Silk Road: Suzhou, Revitalize the ancient city with industrial upgrade

Bitget Wallet Quick Buy Expands Fiat Support to Include EUR/RUB/JPY Currencies

Chief Executives of Hundreds of Cities Jointly Kick Off Smart City Innovation Program Powered by Huawei Pangu Government Model

PayU India to power Seamless & Native Payment Experience on WhatsApp Business Platform

Newly inaugurated Yashobhoomi (IICC Dwarka) to host Trescon's DATE 2023 with Finance Minister Smt. Nirmala Sitharaman amongst the dignitaries

The International Gas Union (IGU) today releases its 2023 Global Wholesale Gas Price Survey report

India-focused private equity and VC funds raised $8.5bn in 2022, the highest ever annual fundraising value - Preqin reports

Uniken Selected as Strategic Mobile and Cybersecurity Partner for Indian Government Initiative

UST Vision Checkout AI-Enabled Autonomous Retail Solution Implemented at Jackson Hole Airport Restaurant

CoinScan Emerges from Stealth with $6.3 Million in Funding

Vestinda Bridges Web3 and Traditional Finance with Support for 100,000 Asset Pairs

Satma CE announces partnership with Refillable to revolutionize Inventory and Refill Management

NMIMS MPSTME Hosts India Automation Games 2023, Inspires the Future of Automation

RateGain shares Pulse Report for India; Global events drive domestic demand higher by 60%

A Star-Studded Affair: Illusion Aligners Honours its Brand Ambassador Kareena Kapoor Khan in Glittering Bollywood Style

Additional story DLC for Resident Evil 4 out now, offers new exhilarating action and different play feel

Introducing VM Social: The Future of Smart Trading

4i Apps Achieves Remarkable Milestone: Wins Oracle Cloud Partner Award 2023 at Oracle Cloud World 2023

VNOAI proposal for increasing BSNL revenues and market share

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
'Women's empowerment is inseparable part...
Karnataka JD(S) VPresigns after party j...
Kolkata: Jadavpur University starts inst...
Indias G20 Presidency provided opportun...
Scuffle breaks out at Delhi store over i...
When I take you for a month... PM Modi...
More...    
 
 Top Stories
Hilsa imports likely to fall as Ban... 
India's engagement with Global Sout... 
Karnataka: Mandya farmers continue ... 
Gujarat: BSF apprehends Pakistani n... 
Andhra Pradesh: TDP leaders hold ca... 
"No right to insult new Parliament"... 
"New partnership to help amplify In... 
Haryana CM Khattar reacts to state ...